|
|
| Name of Committee | Circulatory System Devices Panel |
| Date and Time | The meeting was held on the following dates:
Nov 20, 2003 9:00 AM - 5:00 PM
|
| Location | Hilton Washington DC North/Gaithersburg, Grand Ballroom
620 Perry Parkway
Gaithersburg
, MD |
| Contact Information | Geretta Wood, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8320, ext. 143, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12625. Please call the Information Line for up-to-date information on this meeting. |
| Agenda | The committee will discuss, make recommendations, and vote on a premarket approval application for a drug-eluting stent indicated for improving luminal diameter and reducing restenosis for the treatment of de novo lesions. Background information for the topic, including the agenda and questions for the committee, will be available to the public one business day before the meeting on the Internet at http://www.fda.gov/cdrh/panelmtg.html. Material will be posted on November 19, 2003. |
| Procedure | Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 10, 2003. Oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of committee deliberations and for approximately 30 minutes near the end of the deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 10, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. |
| | Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. |
| Conduct | FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/ for procedures on public conduct during advisory committee meetings. |
| Related Documents |
| Agenda: | |  |
| Briefing: | | |
| Questions: | |  |
| Roster: | | |
| Summary: | | |
| Summary: | | |
| Summary: | | |
| Transcript: | | |
|
| Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). |
|
